JP2012509687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509687A5 JP2012509687A5 JP2011538599A JP2011538599A JP2012509687A5 JP 2012509687 A5 JP2012509687 A5 JP 2012509687A5 JP 2011538599 A JP2011538599 A JP 2011538599A JP 2011538599 A JP2011538599 A JP 2011538599A JP 2012509687 A5 JP2012509687 A5 JP 2012509687A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- group
- protein
- activin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 235000018102 proteins Nutrition 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 16
- 108090000623 proteins and genes Proteins 0.000 claims 16
- 102000040430 polynucleotide Human genes 0.000 claims 14
- 108091033319 polynucleotide Proteins 0.000 claims 14
- 239000002157 polynucleotide Substances 0.000 claims 14
- 235000001014 amino acid Nutrition 0.000 claims 13
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 10
- 108010056852 Myostatin Proteins 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 238000006467 substitution reaction Methods 0.000 claims 10
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims 9
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 9
- 108010023082 activin A Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 108010059616 Activins Proteins 0.000 claims 5
- 102100026818 Inhibin beta E chain Human genes 0.000 claims 5
- 239000000488 activin Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 206010028289 Muscle atrophy Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 201000000585 muscular atrophy Diseases 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010002261 Androgen deficiency Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 206010065687 Bone loss Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000005486 microgravity Effects 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20025008P | 2008-11-26 | 2008-11-26 | |
| US61/200,250 | 2008-11-26 | ||
| US25906009P | 2009-11-06 | 2009-11-06 | |
| US61/259,060 | 2009-11-06 | ||
| PCT/US2009/006252 WO2010062383A2 (en) | 2008-11-26 | 2009-11-24 | Stabilized receptor polypeptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014177598A Division JP5969557B2 (ja) | 2008-11-26 | 2014-09-02 | アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509687A JP2012509687A (ja) | 2012-04-26 |
| JP2012509687A5 true JP2012509687A5 (enExample) | 2012-12-27 |
| JP5611222B2 JP5611222B2 (ja) | 2014-10-22 |
Family
ID=41693455
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011538599A Expired - Fee Related JP5611222B2 (ja) | 2008-11-26 | 2009-11-24 | アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用 |
| JP2014177598A Expired - Fee Related JP5969557B2 (ja) | 2008-11-26 | 2014-09-02 | アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用 |
| JP2016134684A Ceased JP2016199577A (ja) | 2008-11-26 | 2016-07-07 | アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014177598A Expired - Fee Related JP5969557B2 (ja) | 2008-11-26 | 2014-09-02 | アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用 |
| JP2016134684A Ceased JP2016199577A (ja) | 2008-11-26 | 2016-07-07 | アクチビンｉｉｂ受容体ポリペプチドの変異体及びその使用 |
Country Status (37)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EA201692543A1 (ru) | 2005-11-23 | 2017-08-31 | Акселерон Фарма Инк. | Антагонисты активина-actriia и их применение для стимулирования роста кости |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| CA2677007A1 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| CA3039330C (en) | 2007-02-09 | 2021-11-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
| JP5922928B2 (ja) | 2008-08-14 | 2016-05-24 | アクセルロン ファーマ， インコーポレイテッド | 赤血球レベルを高めるためのｇｄｆトラップの使用 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| ME02652B (me) | 2008-11-26 | 2017-06-20 | Amgen Inc | Stabilizovana varijanta aktivin iib receptora |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| EP3153578A1 (en) | 2010-07-06 | 2017-04-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
| CA2808382A1 (en) | 2010-08-16 | 2012-02-23 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| JP6145112B2 (ja) | 2011-12-19 | 2017-06-07 | アムジエン・インコーポレーテツド | 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用 |
| US9453080B2 (en) | 2012-06-11 | 2016-09-27 | Amgen Inc. | Dual receptor antagonistic antigen-binding proteins and uses thereof |
| MX366336B (es) | 2012-11-02 | 2019-07-05 | Celgene Corp | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. |
| US20140220033A1 (en) * | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an Anti-Activin-A Compound to a Subject |
| CA2899889A1 (en) * | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an anti-activin-a compound to a subject |
| TWI655207B (zh) * | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| CN104693270B (zh) * | 2013-12-10 | 2018-10-16 | 清华大学 | 一种用于融合蛋白的连接肽 |
| WO2015108972A1 (en) * | 2014-01-14 | 2015-07-23 | Santa Maria Biotherapeutics, Inc. | Activin inhibitor response prediction and uses for treatment |
| AU2015274293A1 (en) * | 2014-06-13 | 2017-02-02 | Amgen Inc. | Formulated receptor polypeptides and related methods |
| AU2015274277B2 (en) | 2014-06-13 | 2021-03-18 | Acceleron Pharma, Inc. | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| KR102698387B1 (ko) | 2015-02-06 | 2024-08-22 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도 |
| JP6810702B2 (ja) | 2015-04-06 | 2021-01-06 | アクセルロン ファーマ インコーポレイテッド | シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用 |
| BR112017021510A2 (pt) | 2015-04-06 | 2018-07-03 | Acceleron Pharma Inc | heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| RS61881B1 (sr) | 2015-04-22 | 2021-06-30 | Biogen Ma Inc | Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića |
| KR102457751B1 (ko) | 2016-03-10 | 2022-10-21 | 악셀레론 파마 인코포레이티드 | 액티빈 타입 2 수용체 결합 단백질 및 이의 용도 |
| EP3522913A4 (en) | 2016-10-05 | 2020-10-28 | Acceleron Pharma Inc. | ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| EP3538123A4 (en) | 2016-11-10 | 2020-10-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE |
| CA3082146A1 (en) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| CN120399032A (zh) | 2018-01-12 | 2025-08-01 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
| EP3790572A4 (en) | 2018-05-09 | 2022-03-16 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF |
| CN109320597B (zh) * | 2018-10-26 | 2021-10-26 | 中国农业科学院特产研究所 | 狐亚科激活素a蛋白及其制备与应用 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| US20250041385A1 (en) | 2021-12-10 | 2025-02-06 | Biogen Ma Inc. | Modified actrii proteins and methods of use thereof |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US5750375A (en) | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
| JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| WO1994009817A1 (en) | 1992-11-04 | 1994-05-11 | City Of Hope | Novel antibody construct |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| CA2157577C (en) | 1993-03-19 | 2009-11-17 | Se-Jin Lee | Growth differentiation factor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| ATE378407T1 (de) | 1994-04-29 | 2007-11-15 | Curis Inc | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| ES2288036T5 (es) | 1998-11-13 | 2017-07-06 | Immunex Corporation | ADN de TSLP humano y polipéptidos |
| BR0008188A (pt) | 1999-01-21 | 2002-02-13 | Metamorphix Inc | Inibidores de fator de diferenciação de crescimento e usos para os mesmos |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| GB0209896D0 (en) | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| EP2272864A3 (en) | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
| US7785587B2 (en) | 2003-06-02 | 2010-08-31 | Wyeth | Therapeutic methods for muscular or neuromuscular disorders |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| BRPI0406606A (pt) | 2003-11-13 | 2005-12-06 | Hanmi Pharm Ind Co Ltd | Composição farmacêutica compreendendo uma região fc de imunoglobulina como um veìculo |
| ES2551852T3 (es) | 2004-07-23 | 2015-11-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| US20060034831A1 (en) | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
| WO2006036834A2 (en) | 2004-09-24 | 2006-04-06 | Amgen Inc. | MODIFIED Fc MOLECULES |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| DK1933871T3 (da) | 2005-09-07 | 2013-07-08 | Amgen Fremont Inc | Humane monoklonale antistoffer mod activin-receptor-lignende kinase-1 |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| ZA200806837B (en) * | 2006-03-02 | 2009-11-25 | Ishihara Sangyo Kaisha | Solid herbicidal composition |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| EP2468291B1 (en) | 2006-12-18 | 2017-11-22 | Acceleron Pharma, Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| US8501678B2 (en) * | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| TWI573802B (zh) * | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US8318135B2 (en) * | 2007-03-19 | 2012-11-27 | National Research Council Of Canada | Antagonist of ligands and uses thereof |
| CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
| KR20100090683A (ko) | 2007-11-09 | 2010-08-16 | 제넨테크, 인크. | 액티빈 수용체-유사 키나제-ｉ 길항제 조성물 및 사용 방법 |
| US20100008918A1 (en) | 2008-06-26 | 2010-01-14 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| JP5922928B2 (ja) | 2008-08-14 | 2016-05-24 | アクセルロン ファーマ， インコーポレイテッド | 赤血球レベルを高めるためのｇｄｆトラップの使用 |
| ME02652B (me) | 2008-11-26 | 2017-06-20 | Amgen Inc | Stabilizovana varijanta aktivin iib receptora |
| EP2387412A4 (en) | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | PROCESS FOR INCREASING THE ADIPONECTIN MIRROR |
| NO2424895T3 (enExample) | 2009-04-27 | 2018-02-03 | ||
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| US20120295814A1 (en) | 2010-01-08 | 2012-11-22 | The Brigham And Women's Hospital, Inc. | CA-125 Immune Complexes as Biomarkers of Ovarian Cancer |
| WO2011123691A1 (en) | 2010-03-31 | 2011-10-06 | Keryx Biopharmaceuticals, Inc. | Perifosine and capecitabine as a combined treatment for cancer |
| CN103298832A (zh) | 2010-11-08 | 2013-09-11 | 阿塞勒隆制药公司 | Actriia结合剂及其用途 |
| EP2802308A1 (en) | 2012-01-13 | 2014-11-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
| US9401875B2 (en) | 2012-06-01 | 2016-07-26 | Nippon Telegraph And Telephone Corporation | Packet transfer processing method and packet transfer processing device |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2009
- 2009-11-24 ME MEP-2016-243A patent/ME02652B/me unknown
- 2009-11-24 CN CN201410462932.8A patent/CN104371024A/zh active Pending
- 2009-11-24 SG SG2011037777A patent/SG171813A1/en unknown
- 2009-11-24 CA CA2743850A patent/CA2743850C/en not_active Expired - Fee Related
- 2009-11-24 NZ NZ627111A patent/NZ627111A/en not_active IP Right Cessation
- 2009-11-24 PL PL09761055T patent/PL2370463T3/pl unknown
- 2009-11-24 WO PCT/US2009/006252 patent/WO2010062383A2/en not_active Ceased
- 2009-11-24 NZ NZ604818A patent/NZ604818A/en not_active IP Right Cessation
- 2009-11-24 RS RS20160909A patent/RS55369B1/sr unknown
- 2009-11-24 DK DK09761055.4T patent/DK2370463T3/en active
- 2009-11-24 KR KR1020117014720A patent/KR101720143B1/ko not_active Expired - Fee Related
- 2009-11-24 AU AU2009320364A patent/AU2009320364B2/en not_active Ceased
- 2009-11-24 PE PE2011001077A patent/PE20120206A1/es not_active Application Discontinuation
- 2009-11-24 MX MX2011005505A patent/MX2011005505A/es active IP Right Grant
- 2009-11-24 JP JP2011538599A patent/JP5611222B2/ja not_active Expired - Fee Related
- 2009-11-24 CA CA2997971A patent/CA2997971A1/en not_active Abandoned
- 2009-11-24 LT LTEP09761055.4T patent/LT2370463T/lt unknown
- 2009-11-24 CR CR20160443A patent/CR20160443A/es unknown
- 2009-11-24 PT PT97610554T patent/PT2370463T/pt unknown
- 2009-11-24 EA EA201100832A patent/EA201100832A1/ru unknown
- 2009-11-24 PE PE2015000401A patent/PE20150680A1/es not_active Application Discontinuation
- 2009-11-24 KR KR1020177025044A patent/KR20170105124A/ko not_active Abandoned
- 2009-11-24 BR BRPI0920962A patent/BRPI0920962A2/pt not_active IP Right Cessation
- 2009-11-24 UA UAA201107872A patent/UA107921C2/ru unknown
- 2009-11-24 EP EP16179980.4A patent/EP3101029B1/en active Active
- 2009-11-24 HR HRP20161450TT patent/HRP20161450T1/hr unknown
- 2009-11-24 HU HUE09761055A patent/HUE032090T2/en unknown
- 2009-11-24 EA EA201791940A patent/EA201791940A3/ru unknown
- 2009-11-24 AR ARP090104527A patent/AR074397A1/es not_active Application Discontinuation
- 2009-11-24 SG SG10201703067QA patent/SG10201703067QA/en unknown
- 2009-11-24 MA MA33960A patent/MA32936B1/fr unknown
- 2009-11-24 EP EP09761055.4A patent/EP2370463B1/en active Active
- 2009-11-24 MY MYPI2011002346A patent/MY159483A/en unknown
- 2009-11-24 KR KR1020177007651A patent/KR101778134B1/ko not_active Expired - Fee Related
- 2009-11-24 SI SI200931546A patent/SI2370463T1/sl unknown
- 2009-11-24 CN CN200980147945.3A patent/CN102245634B/zh not_active Expired - Fee Related
- 2009-11-24 ES ES09761055.4T patent/ES2600491T3/es active Active
- 2009-11-25 US US12/626,375 patent/US8410043B2/en active Active
- 2009-11-26 TW TW098140431A patent/TWI486166B/zh not_active IP Right Cessation
-
2011
- 2011-05-08 IL IL212773A patent/IL212773A/en not_active IP Right Cessation
- 2011-05-12 TN TN2011000238A patent/TN2011000238A1/fr unknown
- 2011-05-26 CL CL2011001239A patent/CL2011001239A1/es unknown
- 2011-06-23 CO CO11079058A patent/CO6382163A2/es not_active Application Discontinuation
- 2011-06-23 ZA ZA2011/04648A patent/ZA201104648B/en unknown
- 2011-06-24 CR CR20110364A patent/CR20110364A/es unknown
-
2013
- 2013-02-25 US US13/775,756 patent/US9273114B2/en active Active
-
2014
- 2014-09-02 JP JP2014177598A patent/JP5969557B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-22 US US15/004,375 patent/US10308704B2/en active Active
- 2016-07-07 JP JP2016134684A patent/JP2016199577A/ja not_active Ceased
- 2016-09-29 IL IL248128A patent/IL248128A0/en unknown
- 2016-11-16 CY CY20161101175T patent/CY1118754T1/el unknown
- 2016-11-16 SM SM201600417T patent/SMT201600417B/it unknown
-
2019
- 2019-04-18 US US16/388,561 patent/US11685770B2/en active Active
-
2023
- 2023-06-07 US US18/206,963 patent/US20230295267A1/en active Pending